InflaRx (NASDAQ:IFRX) Rating Lowered to Hold at Zacks Research

Key Points

• Zacks Research downgraded InflaRx from “strong buy” to “hold,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $7.33.
• InflaRx shares opened at $2.42, up from their 50-day and 200-day moving averages, but the company reported a quarterly loss of $0.11 per share, missing estimates by $0.04.
• Institutional investors own 42.39% of InflaRx, with several hedge funds recently initiating or increasing positions in the clinical-stage biopharmaceutical company.

InflaRx (NASDAQ:IFRX - Get Free Report) was downgraded by stock analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

IFRX has been the topic of several other research reports. Raymond James Financial upgraded InflaRx from an "outperform" rating to a "strong-buy" rating and boosted their price target for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. HC Wainwright upped their target price on InflaRx from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Wall Street Zen upgraded InflaRx from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Wednesday, June 24th. Finally, Cantor Fitzgerald upped their price target on shares of InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.33.

InflaRx Stock Performance

IFRX stock opened at $2.42 on Tuesday. The firm has a market cap of $356.64 million, a P/E ratio of -4.17 and a beta of 2.48. The stock's 50 day moving average price is $1.97 and its 200 day moving average price is $1.64. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, research analysts predict that InflaRx will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On InflaRx

A number of hedge funds and other institutional investors have recently modified their holdings of IFRX. Cubist Systematic Strategies LLC increased its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after buying an additional 7,616 shares during the period. Woodline Partners LP acquired a new stake in shares of InflaRx in the 1st quarter worth approximately $766,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of InflaRx in the 2nd quarter worth approximately $262,000. Squarepoint Ops LLC boosted its holdings in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company's stock valued at $253,000 after acquiring an additional 42,489 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of InflaRx in the third quarter valued at approximately $214,000. 42.39% of the stock is currently owned by institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source